The NaaS Methodology applied to modeling chemotherapy-induced peripheral neuropathy with human hiPSC neurons

Abstract

The Neuron-as-a-Sensor (NaaS) methodology is a human-relevant platform designed to detect compound-induced effects by capturing functional changes in neuronal activity. This is achieved by integrating hiPSC-derived neuronal cultures, compartmentalized MEA microfluidic devices, a detailed electrophysiology paradigm and a standardized analysis pipeline. Applied to chemotherapy-induced peripheral neuropathy (CIPN), NaaS leverages electrophysiological profiling to capture alterations in neuronal excitability beyond cytotoxicity. Using paclitaxel and oxaliplatin as reference compounds, we demonstrated drug-specific, time-dependent changes in spontaneous and thermally evoked activity that align with their distinct clinical neuropathic phenotypes. Dimensionality reduction of electrophysiological metrics enabled construction of a functional discrimination map, allowing robust separation of compound signatures from vehicle controls. These findings highlight the ability of NaaS to model clinically relevant neurotoxic effects in a scalable manner, supporting its application in both adverse effect prediction and therapeutic screening.